Abstract

Merit Medical will report second-quarter 2026 results on July 30, 2026 Post Market; consensus points to mid-single-digit revenue growth with improving margins and EPS momentum, while investors watch mix shifts between core and therapy portfolios.

Market Forecast

Based on current quarter forecasts, Merit Medical is expected to deliver revenue of 405.27 million US dollars, up 8.53% year over year; EBIT of 78.93 million US dollars, up 17.09% year over year; and adjusted EPS of 0.96, up 12.76% year over year. Management’s mix focus suggests stable-to-better gross margin and continued operating leverage, with adjusted EPS growth outpacing revenue on scale efficiencies.

Merit Medical’s core product and therapy portfolios are expected to maintain growth, with emphasis on higher-margin categories supporting margin expansion. The therapy segment shows the most promising trajectory given the company’s innovation cadence and procedure growth, positioning it as a key driver of incremental revenue and profitability.

Last Quarter Review

In the previous quarter, Merit Medical reported revenue of 381.88 million US dollars (up 7.47% year over year), a gross profit margin of 48.39%, GAAP net profit attributable to shareholders of 40.99 million US dollars with a net profit margin of 10.74%, and adjusted EPS of 0.94 (up 9.30% year over year). Revenue mix highlighted consistent demand across portfolios alongside operating leverage that supported both margin and earnings improvement.

Main business performance featured revenue of 255.48 million US dollars in core products and 126.40 million US dollars in therapy products, with the portfolio balance favoring core products by contribution while therapies provided incremental growth catalysts.

Current Quarter Outlook

Main business trajectory and margin dynamics

Revenue is projected at 405.27 million US dollars for the quarter, with year-over-year growth of 8.53%, implying continued demand across procedure-driven categories. The EBIT forecast of 78.93 million US dollars and EPS of 0.96 suggest positive operating leverage and disciplined expense control. Given the prior quarter’s gross margin at 48.39%, the combination of mix improvement and scale should support gross margin stability or modest expansion. Pricing and productivity initiatives remain important levers to offset wage and input cost inflation, while global procedural volumes continue to normalize in hospital and ambulatory settings. The company’s attention to supply chain resiliency and internal manufacturing should help sustain conversion costs and protect product availability in high-volume disposable lines.

Therapy segment as a growth and mix driver

Therapy products, while contributing a smaller share of revenue than core products, are positioned to drive higher incremental margins due to procedure growth in interventional oncology, electrophysiology-adjacent disposables, and structural heart-related accessories. The segment’s growth is expected to outpace the broader portfolio as new products ramp and clinical adoption broadens, reinforcing the forecast for EBIT growth of 17.09% year over year despite revenue growth of 8.53%. As the therapy mix increases, gross margin should benefit from richer ASPs and lower discounting relative to standard core lines. Execution risks include training curves for new devices and timing of hospital value analysis approvals, which can introduce quarter-to-quarter variability; nevertheless, steady order patterns and backlogs in complex procedures underpin the near-term outlook.

Stock-price sensitivities this quarter

The stock is likely to react to evidence of sustained margin expansion and confirmation that adjusted EPS growth continues to exceed revenue growth. Commentary on order momentum in therapies, as well as visibility into the second-half pipeline cadence, will be closely watched for indications of durability in high-margin categories. Any updates on manufacturing efficiency projects and logistics normalization could influence sentiment on gross margin. Additionally, guidance for full-year revenue and adjusted EPS, especially the magnitude of any raise versus prior commentary, will shape investor expectations for operating leverage through the back half of the year.

Analyst Opinions

The balance of recent institutional commentary leans bullish, with a majority of published views expecting Merit Medical to exceed or meet revenue and adjusted EPS forecasts while demonstrating incremental margin gains. Analysts highlight that the consensus revenue estimate of 405.27 million US dollars and adjusted EPS of 0.96 reflect prudent assumptions, leaving room for upside if therapy adoption trends accelerate and cost efficiencies hold. Several well-followed institutions point to improving EBIT growth relative to revenue growth as a favorable setup, noting that operating leverage and product mix are working in Merit Medical’s favor this quarter.

Bullish views emphasize three elements: sustained demand across procedure-driven categories, a measured yet improving mix toward therapies with richer margins, and tightening execution in manufacturing and supply chain that supports gross margin stability. Analysts also underscore that the prior quarter’s beat versus internal benchmarks in revenue and earnings provides a constructive base heading into this print. Should guidance for the remainder of 2026 be reiterated or modestly lifted, the majority expects positive reaction as it would validate the thesis of accelerating profitability on mid-single to high-single-digit top-line growth.